Ignite Creation Date:
2024-05-05 @ 11:41 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00108264
Status:
COMPLETED
Last Update Posted:
2009-01-21
First Post:
2005-04-14
Brief Title:
Tumor RNA Transfected Dendritic Cell Vaccines
Sponsor:
US Department of Veterans Affairs
Organization:
VA Office of Research and Development
Study Overview
Official Title:
Tumor RNA Transfected Dendritic Cell Vaccines
Status:
COMPLETED
Status Verified Date:
2007-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to use dendritic cells transfected with amplified RNA from autologous tumor cells to develop a vaccine strategy for the treatment of prostate cancer in patients with disseminated disease
Detailed Description:
The specific aims are 1 to evaluate in a phase I clinical trial the safety of vaccinating patients with dendritic cells transfected with RNA from autologous cancer cells 2 to analyze the T cell responses induced by the treatment and 3 to improve the efficacy of the treatment by developing methods to increase the induction of CD4T cell responses
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None